sumatriptan has been researched along with Allodynia in 37 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of these studies was to evaluate the effects of the 5-HT(1B/1D) receptor agonist sumatriptan in specific models of pain states: a mouse model of inflammation-induced thermal hyperalgesia and a rat model of nerve injury-induced thermal hyperalgesia." | 7.71 | Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors. ( Bingham, S; Davey, PT; Overend, P; Parsons, AA; Raval, P; Sammons, M, 2001) |
| "Using nitroglycerine to trigger migraine attacks, we investigated whether cranial allodynia could be triggered experimentally, observing its response to treatment." | 6.90 | Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity. ( Akerman, S; Bose, P; Goadsby, PJ; Hoffmann, JR; Holland, PR; Karsan, N; Romero-Reyes, M, 2019) |
| "Our data suggest that sumatriptan reduces central sensitization (secondary hyperalgesia) without modulating peripheral sensitization (primary hyperalgesia) in a human pain model of capsaicin-induced sensitization." | 5.51 | Sumatriptan prevents central sensitization specifically in the trigeminal dermatome in humans. ( Basedau, H; Jürgens, T; May, A; Ortlieb, L; Peng, KP, 2022) |
| "This study evaluated the effectiveness of a single fixed-dose tablet of sumatriptan 85 mg/naproxen sodium 500 mg (sumatriptan-naproxen) using a very early treatment paradigm in migraine patients whose attacks were historically accompanied by cutaneous allodynia." | 5.16 | Sumatriptan-naproxen migraine efficacy in allodynic patients: early intervention. ( Hoagland, NA; Hoagland, R; Landy, S, 2012) |
| " Each migraineur treated 2 migraine headaches with sumatriptan (100 mg): 1 headache at the earliest sign of migraine pain (mild, within 1 hour of onset) and 1 headache at least 4 hours after the onset of pain while moderate or severe." | 5.12 | Clarification of developing and established clinical allodynia and pain-free outcomes. ( Landy, SH; McDonald, SA; McGinnis, JE, 2007) |
| "In a pre-clinical rat model of MOH, oral lasmiditan, like sumatriptan, induced acute transient cutaneous allodynia in the periorbital and hindpaw regions that after resolution could be re-evoked by putative migraine triggers." | 3.96 | Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache. ( Aurora, SK; Dodick, DW; Johnson, KW; Navratilova, E; Oyarzo, J; Porreca, F; Rau, JC; Schwedt, TJ, 2020) |
| "Sumatriptan elicited cutaneous allodynia in both cephalic and hindpaw regions; cutaneous allodynia resolved to baseline levels after cessation of drug administration (14 days)." | 3.96 | Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. ( Banerjee, P; Behravesh, S; Dodick, DW; Navratilova, E; Oyarzo, J; Porreca, F, 2020) |
| " Methods We assessed in rats the roles of dose and repeat administration of systemic isosorbide dinitrate (ISDN), a nitric oxide donor, on the occurrence and development of cephalic/face and extracephalic/hindpaw mechanical allodynia as a surrogate of migraine pain, and the effect of acute systemic sumatriptan and olcegepant and chronic systemic propranolol on these behavioral changes." | 3.88 | Recurrent administration of the nitric oxide donor, isosorbide dinitrate, induces a persistent cephalic cutaneous hypersensitivity: A model for migraine progression. ( Dallel, R; Descheemaeker, A; Luccarini, P, 2018) |
| " Results VL-102-evoked acute and chronic mechanical cephalic and hind-paw allodynia in a dose-dependent manner, which was blocked by the migraine medications sumatriptan, propranolol, and topiramate." | 3.88 | Soluble guanylyl cyclase is a critical regulator of migraine-associated pain. ( Ben Aissa, M; Bennett, BM; Bertels, Z; Gaisina, IN; Gandhi, R; Lee, SH; Litosh, V; Moye, LS; Novack, M; Pradhan, AA; Thatcher, GR; Tipton, AF; Wang, Y, 2018) |
| " This project investigates the safety and effectiveness of pulsed focused ultrasound (FUS) in a validated rodent headache model of cutaneous allodynia associated with chronic migraine (CM) as compared to sumatriptan and ablative lesioning." | 3.88 | The use of focused ultrasound for the treatment of cutaneous allodynia associated with chronic migraine. ( Burdette, C; Frith, L; Gannon, S; Gee, L; Ghoshal, G; Hellman, A; Kaszuba, B; Kumar, V; Maietta, T; Neubauer, P; Panse, D; Pilitsis, JG; Qian, J; Shin, DS; Walling, I; Williams, E, 2018) |
| "The present study showed that repeated IS stimulations induced long-lasting allodynia, increased BBB permeability, and upregulated VEGF expression, all of which could be attenuated by early sumatriptan treatment." | 3.88 | Recurrent Headache Increases Blood-Brain Barrier Permeability and VEGF Expression in Rats. ( Chen, L; Mi, X; Qin, G; Ran, L, 2018) |
| "Ipsilateral, but not contralateral, pre-treatment (in μg/paw) with sumatriptan (10-300), methysergide (1-30) or dihydroergotamine (1-30) significantly prevented flinching behavior (at 1h) as well as secondary allodynia and hyperalgesia (at day 6) induced by formalin." | 3.79 | Role of 5-HT₁B/₁D receptors in the reduction of formalin-induced nociception and secondary allodynia/hyperalgesia produced by antimigraine drugs in rats. ( Argüelles, CF; Godínez-Chaparro, B; Granados-Soto, V; López-Santillán, FJ; Villalón, CM, 2013) |
| " The aim of these studies was to evaluate the effects of the 5-HT(1B/1D) receptor agonist sumatriptan in specific models of pain states: a mouse model of inflammation-induced thermal hyperalgesia and a rat model of nerve injury-induced thermal hyperalgesia." | 3.71 | Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors. ( Bingham, S; Davey, PT; Overend, P; Parsons, AA; Raval, P; Sammons, M, 2001) |
| "Using nitroglycerine to trigger migraine attacks, we investigated whether cranial allodynia could be triggered experimentally, observing its response to treatment." | 2.90 | Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity. ( Akerman, S; Bose, P; Goadsby, PJ; Hoffmann, JR; Holland, PR; Karsan, N; Romero-Reyes, M, 2019) |
| "Only ketorolac NS was superior to placebo for 24-hour (ketorolac: 35." | 2.82 | A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine. ( Dash, PD; Gelaye, B; Kurth, T; Nitchie, H; Peterlin, BL; Rao, AS, 2016) |
| "The paradigm of early treatment of the migraine attack at mild pain intensity has become one alternative to circumventing the problem of compromised oral absorption of symptomatic drugs due to migraine-induced gastrointestinal dysmotility." | 2.43 | Cutaneous allodynia and migraine: another view. ( Dahlöf, C, 2006) |
| "The majority of patients with chronic migraine and medication overuse headache are female." | 1.72 | A prolactin-dependent sexually dimorphic mechanism of migraine chronification. ( Dodick, DW; Ikegami, D; Khanna, R; Kopruszinski, CM; Moutal, A; Navratilova, E; Patwardhan, A; Porreca, F; Yue, X, 2022) |
| "Pretreatment with propranolol or nor-BNI prior to restraint stress prevented both transient cutaneous allodynia and priming, demonstrated by a lack of umbellulone-induced cutaneous allodynia." | 1.62 | A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. ( Chessell, IP; Dodick, DW; Kopruszinski, CM; Navratilova, E; Porreca, F; Swiokla, J, 2021) |
| "Migraine is one of the most disabling disorders worldwide but the underlying mechanisms are poorly understood." | 1.56 | Repetitive stress in mice causes migraine-like behaviors and calcitonin gene-related peptide-dependent hyperalgesic priming to a migraine trigger. ( Akopian, AN; Avona, A; Burgos-Vega, C; Dussor, G; Garcia-Martinez, LF; Lackovic, J; Mason, BN; Moldovan Loomis, C; Motina, M; Price, TJ; Quigley, L; Wajahat, N, 2020) |
| "Morphine was more detrimental than sumatriptan, consistent with clinical observations of higher medication overuse headache risk with opioids." | 1.51 | Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache. ( Dodick, DW; Nation, KM; Navratilova, E; Porreca, F, 2019) |
| "Sumatriptan, an acute migraine treatment blocked acute blood flow changes in response to TRPA1 or transient receptor potential vanilloid receptor-1 agonists." | 1.48 | Induction of chronic migraine phenotypes in a rat model after environmental irritant exposure. ( Hurley, JH; Johnson, PL; Kunkler, PE; Oxford, GS; Zhang, L, 2018) |
| "Cutaneous allodynia (CA) was used as an outcome measure and CGRP blood and cerebrospinal fluid (CSF) levels were measured." | 1.46 | Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. ( Bigal, M; Chichorro, JG; Dodick, D; Eyde, NM; Kopruszinski, CM; Porreca, F; Remeniuk, B; Stratton, J; Walter, S; Xie, JY, 2017) |
| "Trigeminal allodynia and photosensitivity were measured." | 1.43 | Trigeminal Pain Molecules, Allodynia, and Photosensitivity Are Pharmacologically and Genetically Modulated in a Model of Traumatic Brain Injury. ( Clark, SW; Daiutolo, BV; Elliott, MB; Tyburski, A, 2016) |
| "We reported that hyperalgesia induced by intradermal GTN has a delay to onset of ∼ 30 min in male and ∼ 45 min in female rats." | 1.43 | Mechanisms mediating nitroglycerin-induced delayed-onset hyperalgesia in the rat. ( Ferrari, LF; Green, PG; Levine, JD, 2016) |
| "The prolongation of PGE2 hyperalgesia was also permanently reversed by intradermal injection of cordycepin, a protein translation inhibitor." | 1.43 | Gi-protein-coupled 5-HT1B/D receptor agonist sumatriptan induces type I hyperalgesic priming. ( Araldi, D; Ferrari, LF; Levine, JD, 2016) |
| "Chronic migraine is a disabling condition that affects hundreds of millions of individuals worldwide." | 1.40 | Characterization of a novel model of chronic migraine. ( Charles, A; Evans, CJ; McGuire, B; Pradhan, AA; Smith, ML; Tarash, I, 2014) |
| "We found that epinephrine also produces hyperalgesia and SIEH." | 1.39 | Role of endothelial cells in antihyperalgesia induced by a triptan and β-blocker. ( Joseph, EK; Levine, JD, 2013) |
| "Peripherally released 5HT induces thermal hyperalgesia, possibly via modulation of the transient receptor potential V1 (TRPV1) channel, which is gated by various noxious stimuli, including capsaicin." | 1.38 | Anti-hyperalgesic effects of anti-serotonergic compounds on serotonin- and capsaicin-evoked thermal hyperalgesia in the rat. ( Chen, PB; Hargreaves, KM; Loyd, DR, 2012) |
| "Tail flick latency, an index of hyperalgesia, was assessed using analgesiometer." | 1.35 | Possible role of spleen-derived factors, vanilloid receptors and calcitonin gene-related peptide in diabetes induced hyperalgesia in mice. ( Jaggi, AS; Khan, N; Singh, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.70) | 18.2507 |
| 2000's | 6 (16.22) | 29.6817 |
| 2010's | 22 (59.46) | 24.3611 |
| 2020's | 8 (21.62) | 2.80 |
| Authors | Studies |
|---|---|
| Ikegami, D | 1 |
| Navratilova, E | 5 |
| Yue, X | 1 |
| Moutal, A | 1 |
| Kopruszinski, CM | 3 |
| Khanna, R | 1 |
| Patwardhan, A | 1 |
| Dodick, DW | 5 |
| Porreca, F | 6 |
| Peng, KP | 1 |
| Jürgens, T | 1 |
| Basedau, H | 1 |
| Ortlieb, L | 1 |
| May, A | 1 |
| Araya, EI | 1 |
| Turnes, JM | 1 |
| Barroso, AR | 1 |
| Chichorro, JG | 2 |
| Avona, A | 1 |
| Mason, BN | 1 |
| Lackovic, J | 1 |
| Wajahat, N | 1 |
| Motina, M | 1 |
| Quigley, L | 1 |
| Burgos-Vega, C | 1 |
| Moldovan Loomis, C | 1 |
| Garcia-Martinez, LF | 1 |
| Akopian, AN | 1 |
| Price, TJ | 1 |
| Dussor, G | 1 |
| Rau, JC | 1 |
| Oyarzo, J | 2 |
| Johnson, KW | 1 |
| Aurora, SK | 1 |
| Schwedt, TJ | 1 |
| Behravesh, S | 1 |
| Banerjee, P | 1 |
| Tang, C | 1 |
| Unekawa, M | 1 |
| Kitagawa, S | 1 |
| Takizawa, T | 1 |
| Kayama, Y | 1 |
| Nakahara, J | 1 |
| Shibata, M | 1 |
| Swiokla, J | 1 |
| Chessell, IP | 1 |
| Dallel, R | 1 |
| Descheemaeker, A | 1 |
| Luccarini, P | 1 |
| Ben Aissa, M | 1 |
| Tipton, AF | 2 |
| Bertels, Z | 1 |
| Gandhi, R | 1 |
| Moye, LS | 2 |
| Novack, M | 1 |
| Bennett, BM | 1 |
| Wang, Y | 1 |
| Litosh, V | 1 |
| Lee, SH | 1 |
| Gaisina, IN | 1 |
| Thatcher, GR | 1 |
| Pradhan, AA | 3 |
| Kunkler, PE | 1 |
| Zhang, L | 1 |
| Johnson, PL | 1 |
| Oxford, GS | 1 |
| Hurley, JH | 1 |
| Walling, I | 1 |
| Panse, D | 1 |
| Gee, L | 1 |
| Maietta, T | 1 |
| Kaszuba, B | 1 |
| Kumar, V | 1 |
| Gannon, S | 1 |
| Hellman, A | 1 |
| Neubauer, P | 1 |
| Frith, L | 1 |
| Williams, E | 1 |
| Ghoshal, G | 1 |
| Shin, DS | 1 |
| Burdette, C | 1 |
| Qian, J | 1 |
| Pilitsis, JG | 1 |
| Nation, KM | 1 |
| Paczkowska, M | 1 |
| Mizera, M | 1 |
| Sałat, K | 1 |
| Furgała, A | 1 |
| Popik, P | 1 |
| Knapik-Kowalczuk, J | 1 |
| Krause, A | 1 |
| Szymanowska-Powałowska, D | 1 |
| Fojud, Z | 1 |
| Kozak, M | 1 |
| Paluch, M | 1 |
| Cielecka-Piontek, J | 1 |
| Mi, X | 1 |
| Ran, L | 1 |
| Chen, L | 1 |
| Qin, G | 1 |
| Dripps, I | 1 |
| Sheets, Z | 1 |
| Crombie, A | 1 |
| Violin, JD | 1 |
| Akerman, S | 1 |
| Karsan, N | 1 |
| Bose, P | 1 |
| Hoffmann, JR | 1 |
| Holland, PR | 1 |
| Romero-Reyes, M | 1 |
| Goadsby, PJ | 2 |
| Godínez-Chaparro, B | 1 |
| López-Santillán, FJ | 1 |
| Argüelles, CF | 1 |
| Villalón, CM | 1 |
| Granados-Soto, V | 1 |
| Smith, ML | 1 |
| McGuire, B | 1 |
| Tarash, I | 1 |
| Evans, CJ | 1 |
| Charles, A | 1 |
| Daiutolo, BV | 1 |
| Tyburski, A | 1 |
| Clark, SW | 1 |
| Elliott, MB | 1 |
| Ferrari, LF | 3 |
| Levine, JD | 4 |
| Green, PG | 1 |
| Rao, AS | 1 |
| Gelaye, B | 1 |
| Kurth, T | 1 |
| Dash, PD | 1 |
| Nitchie, H | 1 |
| Peterlin, BL | 1 |
| Araldi, D | 2 |
| Xie, JY | 1 |
| Eyde, NM | 1 |
| Remeniuk, B | 1 |
| Walter, S | 1 |
| Stratton, J | 1 |
| Bigal, M | 1 |
| Dodick, D | 1 |
| Green, P | 1 |
| Nikai, T | 2 |
| Basbaum, AI | 2 |
| Ahn, AH | 2 |
| Dahlöf, C | 1 |
| Khan, N | 1 |
| Singh, N | 1 |
| Jaggi, AS | 1 |
| Bates, EA | 1 |
| Brennan, KC | 1 |
| Fu, YH | 1 |
| Charles, AC | 1 |
| Ptácek, LJ | 1 |
| Mitsikostas, DD | 1 |
| Knight, YE | 1 |
| Lasalandra, M | 1 |
| Kavantzas, N | 1 |
| Landy, S | 1 |
| Hoagland, R | 1 |
| Hoagland, NA | 1 |
| Loyd, DR | 1 |
| Chen, PB | 1 |
| Hargreaves, KM | 1 |
| Joseph, EK | 1 |
| Linde, M | 1 |
| Elam, M | 1 |
| Lundblad, L | 1 |
| Olausson, H | 1 |
| Dahlöf, CG | 1 |
| Landy, SH | 1 |
| McGinnis, JE | 1 |
| McDonald, SA | 1 |
| Shepheard, S | 1 |
| Edvinsson, L | 1 |
| Cumberbatch, M | 1 |
| Williamson, D | 1 |
| Mason, G | 1 |
| Webb, J | 1 |
| Boyce, S | 1 |
| Hill, R | 1 |
| Hargreaves, R | 1 |
| Bingham, S | 1 |
| Davey, PT | 1 |
| Sammons, M | 1 |
| Raval, P | 1 |
| Overend, P | 1 |
| Parsons, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine (The KSPN Migraine Study)[NCT01807234] | Phase 4 | 72 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome was 2-hour headache relief; headache relief was defined as headache pain from moderate or severe pain to none or mild pain. Pain was assessed using a 4-point scale (none, mild, moderate, and severe) (NCT01807234)
Timeframe: 2 hours
| Intervention | percentage of participants (Number) |
|---|---|
| Ketorolac/ Placebo | 72.5 |
| Sumatriptan/ Placebo | 69.4 |
| Ketorolac Placebo/ Sumatriptan Placebo | 38.8 |
5) Absence of allodynia The presence of allodynia was assessed based on a series of 8 questions inquiring as to the presence of allodynia. Participants answering 2 or more questions positively were considered to have allodynia. (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 70.5 |
| Sumatriptan/ Placebo | 75.5 |
| Ketorolac Placebo/ Sumatriptan Placebo | 69.0 |
4) Defined as reduction of nausea to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe) (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 82.7 |
| Sumatriptan/ Placebo | 74.0 |
| Ketorolac Placebo/ Sumatriptan Placebo | 66.0 |
3) Defined as reduction of phonophobia to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe) (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 75.0 |
| Sumatriptan/Placebo | 66.0 |
| Ketorolac Placebo/ Sumatriptan Placebo | 56.0 |
2) Defined as reduction of photophobia to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe) (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 65.4 |
| Sumatriptan/ Placebo | 64.0 |
| Ketorolac Placebo/ Sumatriptan Placebo | 46.0 |
1) Pain Freedom: Pain Freedom at 2 hours is defined as being free of pain. Pain was assessed using a 4-point scale (none, mild, moderate, and severe). (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 43.1 |
| Sumatriptan/Placebo | 36.7 |
| Ketorolac Placebo/ Sumatriptan Placebo | 18.4 |
Participants' self-assessment of disability was assessed using 4-point scales (none, mild, moderate, and severe). A binary outcome variable was created grouping none and mild vs moderate to severe. . (NCT01807234)
Timeframe: 2-hours
| Intervention | percentage of patients (Number) |
|---|---|
| Ketorolac/ Placebo | 1.9 |
| Sumatriptan/ Placebo | 8.1 |
| Ketorolac Placebo/ Sumatriptan Placebo | 10.2 |
8) 24 and 48 hours sustained pain freedom (SPF); Defined as the reduction of pain to none. Pain was assessed using a 4-point scale (none, mild, moderate, and severe). (NCT01807234)
Timeframe: 24 and 48 hours
| Intervention | percentage of patients (Number) | |
|---|---|---|
| 24 hour sustained pain freedom | 48 hour sustained pain freedom | |
| Ketorolac Placebo/ Sumatriptan Placebo | 12.2 | 12.2 |
| Ketorolac/ Placebo | 35.3 | 33.3 |
| Sumatriptan/ Placebo | 22.4 | 18.4 |
7) 24 and 48 hours sustained pain relief (SPR) Defined as the reduction of pain to none or mild from moderate or severe, on a 4-point scale (none, mild, moderate, and severe). (NCT01807234)
Timeframe: 24 and 48 hours
| Intervention | percentage of patients (Number) | |
|---|---|---|
| 24 hour sustained pain relief | 48 hour sustained pain relief | |
| Ketorolac Placebo/ Sumatriptan Placebo | 20.4 | 20.4 |
| Ketorolac/ Placebo | 49.0 | 49.0 |
| Sumatriptan/ Placebo | 40.8 | 30.6 |
9) The time, in minutes, will be measured from the time study drug is taken to the time when significant pain relief is first observed and maintained through 2 hours with no rescue medication use at or prior to this point. (NCT01807234)
Timeframe: following each treated migraine attack
| Intervention | percentage of patients (Number) | ||||
|---|---|---|---|---|---|
| 10 minutes | 15 minutes | 20 minutes | 30 minutes | 1 hour | |
| Ketorolac Placebo/ Sumatriptan Placebo | 12.2 | 14.3 | 22.4 | 26.5 | 32.6 |
| Ketorolac/ Placebo | 15.7 | 35.3 | 43.1 | 54.9 | 58.8 |
| Sumatriptan/ Placebo | 14.3 | 36.0 | 44.9 | 53.1 | 57.1 |
1 review available for sumatriptan and Allodynia
| Article | Year |
|---|---|
Cutaneous allodynia and migraine: another view.
Topics: Humans; Hyperalgesia; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan | 2006 |
6 trials available for sumatriptan and Allodynia
| Article | Year |
|---|---|
Sumatriptan prevents central sensitization specifically in the trigeminal dermatome in humans.
Topics: Capsaicin; Central Nervous System Sensitization; Headache; Humans; Hyperalgesia; Migraine Disorders; | 2022 |
Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity.
Topics: Adolescent; Adult; Aspirin; Double-Blind Method; Humans; Hyperalgesia; Middle Aged; Migraine Disorde | 2019 |
A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Disability Evaluation; Double-Bl | 2016 |
Sumatriptan-naproxen migraine efficacy in allodynic patients: early intervention.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Disability Evaluation; Drug Therap | 2012 |
Sumatriptan (5-HT1B/1D-agonist) causes a transient allodynia.
Topics: Adult; Cold Temperature; Cross-Sectional Studies; Female; Hot Temperature; Humans; Hyperalgesia; Mal | 2004 |
Clarification of developing and established clinical allodynia and pain-free outcomes.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Female; Health Surveys; Humans; Hyperalgesia; Male; Mid | 2007 |
30 other studies available for sumatriptan and Allodynia
| Article | Year |
|---|---|
A prolactin-dependent sexually dimorphic mechanism of migraine chronification.
Topics: Animals; Female; Headache Disorders, Secondary; Humans; Hyperalgesia; Male; Mice; Migraine Disorders | 2022 |
Contribution of intraganglionic CGRP to migraine-like responses in male and female rats.
Topics: Animals; Calcitonin Gene-Related Peptide; Female; Hyperalgesia; Male; Migraine Disorders; Rats; Rats | 2020 |
Repetitive stress in mice causes migraine-like behaviors and calcitonin gene-related peptide-dependent hyperalgesic priming to a migraine trigger.
Topics: Animals; Calcitonin Gene-Related Peptide; Female; Humans; Hyperalgesia; Male; Mice; Migraine Disorde | 2020 |
Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache.
Topics: Analgesics; Animals; Benzamides; Central Nervous System Sensitization; Disease Models, Animal; Heada | 2020 |
Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache.
Topics: Analgesics; Animals; Central Nervous System Sensitization; Disease Models, Animal; Female; Headache | 2020 |
Cortical spreading depolarisation-induced facial hyperalgesia, photophobia and hypomotility are ameliorated by sumatriptan and olcegepant.
Topics: Animals; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Cere | 2020 |
A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.
Topics: Animals; Calcitonin Gene-Related Peptide; Disease Models, Animal; Female; Hyperalgesia; Male; Mice; | 2021 |
Recurrent administration of the nitric oxide donor, isosorbide dinitrate, induces a persistent cephalic cutaneous hypersensitivity: A model for migraine progression.
Topics: Animals; Central Nervous System Sensitization; Dipeptides; Disease Models, Animal; Hyperalgesia; Iso | 2018 |
Soluble guanylyl cyclase is a critical regulator of migraine-associated pain.
Topics: Adrenergic beta-Antagonists; Allosteric Regulation; Animals; Anticonvulsants; Calcitonin Gene-Relate | 2018 |
Induction of chronic migraine phenotypes in a rat model after environmental irritant exposure.
Topics: Acrolein; Analysis of Variance; Animals; Chronic Disease; Disease Models, Animal; Exploratory Behavi | 2018 |
The use of focused ultrasound for the treatment of cutaneous allodynia associated with chronic migraine.
Topics: Animals; Disease Models, Animal; Hyperalgesia; Male; Migraine Disorders; Pain Threshold; Peripheral | 2018 |
Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache.
Topics: Analgesics; Analgesics, Opioid; Animals; Headache Disorders, Secondary; Hyperalgesia; Male; Migraine | 2019 |
Enhanced pharmacological efficacy of sumatriptan due to modification of its physicochemical properties by inclusion in selected cyclodextrins.
Topics: beta-Cyclodextrins; Calorimetry, Differential Scanning; Chromatography, High Pressure Liquid; Cyclod | 2018 |
Recurrent Headache Increases Blood-Brain Barrier Permeability and VEGF Expression in Rats.
Topics: Animals; Blood-Brain Barrier; Capillary Permeability; Headache; Hyperalgesia; Inflammation; Male; Mi | 2018 |
Delta opioid receptor agonists are effective for multiple types of headache disorders.
Topics: Animals; Benzamides; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Headache Diso | 2019 |
Role of 5-HT₁B/₁D receptors in the reduction of formalin-induced nociception and secondary allodynia/hyperalgesia produced by antimigraine drugs in rats.
Topics: Acute Pain; Animals; Biphenyl Compounds; Chronic Pain; Dihydroergotamine; Disease Models, Animal; Dr | 2013 |
Characterization of a novel model of chronic migraine.
Topics: Animals; Chronic Disease; Disease Models, Animal; Female; Freund's Adjuvant; Hyperalgesia; Male; Mic | 2014 |
Trigeminal Pain Molecules, Allodynia, and Photosensitivity Are Pharmacologically and Genetically Modulated in a Model of Traumatic Brain Injury.
Topics: Animals; Brain Injuries, Traumatic; Calcitonin Gene-Related Peptide; Disease Models, Animal; Hyperal | 2016 |
Mechanisms mediating nitroglycerin-induced delayed-onset hyperalgesia in the rat.
Topics: Animals; Disease Models, Animal; Endothelial Cells; Female; Hyperalgesia; Male; Mast Cells; Neutroph | 2016 |
Gi-protein-coupled 5-HT1B/D receptor agonist sumatriptan induces type I hyperalgesic priming.
Topics: Animals; Chronic Pain; Female; Hyperalgesia; Male; Nociceptors; Pain Threshold; Rats; Rats, Sprague- | 2016 |
Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents.
Topics: Animals; Antibodies, Monoclonal; Calcitonin Gene-Related Peptide; Headache Disorders, Secondary; Hyp | 2017 |
Marked sexual dimorphism in 5-HT
Topics: Animals; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Female; Hyperalgesi | 2017 |
Profound reduction of somatic and visceral pain in mice by intrathecal administration of the anti-migraine drug, sumatriptan.
Topics: Acetic Acid; Analgesics, Non-Narcotic; Animals; Blood-Brain Barrier; Carrageenan; Drug Evaluation, P | 2008 |
Possible role of spleen-derived factors, vanilloid receptors and calcitonin gene-related peptide in diabetes induced hyperalgesia in mice.
Topics: Animals; Calcitonin Gene-Related Peptide; Diabetes Mellitus, Experimental; Female; Hyperalgesia; Mal | 2008 |
Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice.
Topics: Animals; Brain; Cortical Spreading Depression; Gene Expression; Hot Temperature; Hyperalgesia; Immun | 2010 |
Triptans attenuate capsaicin-induced CREB phosphorylation within the trigeminal nucleus caudalis: a mechanism to prevent central sensitization?
Topics: Animals; Capsaicin; Cyclic AMP Response Element-Binding Protein; Hyperalgesia; Immunohistochemistry; | 2011 |
Anti-hyperalgesic effects of anti-serotonergic compounds on serotonin- and capsaicin-evoked thermal hyperalgesia in the rat.
Topics: Animals; Capsaicin; Female; Hyperalgesia; Ketanserin; Male; Pain Measurement; Rats; Rats, Sprague-Da | 2012 |
Role of endothelial cells in antihyperalgesia induced by a triptan and β-blocker.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Endothelial Cells; Endothelin-1; End | 2013 |
Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370.
Topics: Animals; Benzamides; Cerebral Arteries; Decerebrate State; Electric Stimulation; Humans; Hyperalgesi | 1999 |
Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors.
Topics: Analysis of Variance; Animals; Carrageenan; Discriminant Analysis; Disease Models, Animal; Female; H | 2001 |